ASH 2022 | Testing for IgHV and TP53 mutations to guide treatment decisions in CLL
Paolo Ghia, MD, Università Vita-Salute San Raffaele, Milan, Italy, comments on the importance of testing for IgHV and TP53 mutations before treatment in chronic lymphocytic leukemia (CLL), explaining how it may influence treatment selection. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
MSD: Consultancy, Honoraria; Roche: Consultancy, Honoraria; AbbVie: Consultancy, Honoraria, Research Funding; AstraZeneca: Consultancy, Honoraria, Research Funding; Janssen: Consultancy, Honoraria, Research Funding; BeiGene: Consultancy, Honoraria; BMS: Consultancy, Honoraria; Lilly/Loxo: Consultancy, Honoraria.
